Novartis AG (NVS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Novartis AG (NVS) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How NVS Turns Every Dollar of Sales Into Real Bottom-Line Profit
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring NVS)
- ✓Live walkthrough of NVS's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
NVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NVS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NVS. Explore sector supply chains on /butterfly.
NVS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Novartis AG (NVS)?
In Trailing 12 Months, NVS converted $43.0B of revenue into a 41% gross margin, 13.9% operating margin, and $6.8B in free cash flow (15.8% FCF margin).